Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score

Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c (

Saved in:
Bibliographic Details
Published in:EClinicalMedicine 2024-06, Vol.72, p.102625-102625, Article 102625
Main Authors: Ghusn, Wissam, Anazco, Diego, Fansa, Sima, Tama, Elif, Cifuentes, Lizeth, Gala, Khushboo, Calderon, Gerardo, Collazo-Clavell, Maria L., Hurtado, Maria D., Acosta, Andres
Format: Article
Language:English
Subjects:
Diabetes
GLP-1 receptor agonists
Individualized metabolic surgery score
Obesity
Semaglutide
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c (
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2024.102625